DOP001 Effectiveness and safety of vedolizumab in anti-TNF naïve patients with inflammatory bowel disease: a multicentre retrospective European Crohn's and Colitis Organisation study. (16th January 2018)

• Record Type: Journal Article
• Authors: Kopylov, U; Verstockt, B; Biedermann, L; Sebastian, S; Pugliese, D; Sonnenberg, E; Steinhagen, P R; Arebi, N; Ron, Y; Kucharzik, T; Roblin, X; Ungar, B; Bar-Gil Shitrit, A; Ardizzone, S; Molander, P; Coletta, M; Peyrin-Biroulet, L; Bossuyt, P; Avni-Biron, I; Tsoukal, E I; Allocca, M; Katsanos, K; Raine, T; Sipponen, T; Fiorino, G; Ben-Horin, S; Eliakim, R; Armuzzi, A; Siegmund, B; Baumgart, D C; Kamperidis, N; Maharshak, N; Maaser, C; Mantzaris, G; Yanai, H; Christodoulou, D; Dotan, I; Ferrante, M;
• Is Part Of: Journal of Crohn's and colitis. Volume 12:Number 1(2018:Jan.)Supplement 1
• Page Start: S029
• Page End: S030
• Publication Date: 2018-01-16
• Subjects: Inflammatory bowel diseases -- Periodicals; 616.344005
• DOI: 10.1093/ecco-jcc/jjx180.038
• Languages: English
• ISSNs: 1873-9946

Abstract

Abstract: Background: In GEMINI trials, anti-tumour necrosis factor (TNF) naïve CD and UC patients had a superior response compared with anti-TNF-exposed. In real-world experience (RWE) the number of included anti-TNF-naïve patients was low. We aimed to evaluate the effectiveness and safety of VDZ in anti-TNF naïve patients in RWE setting. Methods: This retrospective multicentre European pooled cohort study included consecutive active anti-TNF-naïve IBD patients treated with VDZ. Clinical response at week 14 was defined as the primary outcome. Patients with follow-up beyond week 14 and those discontinuing VDZ at any time were included for last follow-up analysis. The study protocol was reviewed and approved by ECCO Clinical Committee (Clincom). Results: Since January 2015, 184 anti-TNF naïve patients from 23 centres initiated VDZ treatment (CD-50, UC-134). In CD, 42/50 (82%) patients responded by week 14, and 32 (64%) were in clinical remission; 26/50 (52%) achieved corticosteroid-free remission (CSFR) . At last follow-up (44 (IQR 30–52) weeks)), 27/35 (77.1%) patients with available data responded to treatment; 24/35 (68.6%) were in clinical remission, 21/35 (60%) were in CSFR. For UC, 116/134 (79.1%) responded to treatment and 53 (39.5%) were in remiision by week 14; 49/134 (36.6%) achieved CSFR. At last follow-up (42.5 (30–52) weeks)), 79/103 (76.7%) patients responded to treatment, 69/103 (67.0%) were in remission and 61/103 (59.2%) in CSFR. Endoscopic improvement was achieved in 8/11 (63.7%) and mucosl healing in 5/11 (45.5%) CD patients with available baseline/follow-up data. In UC, mucosal healing was achieved in 31/55 (58.5%) patients. Secondary loss of response was developed in 9/90 (10%) patients that continued treatment at week 14 after 39 (32–42) weeks of follow-up. Adverse effects were reported in 20(11%) of the patients, leading to treatment discontinuation in 6(3.3%). Conclusions: VDZ was effective for induction of clinical remission and response in anti-TNF navie patients .The response rates were similar in UC and CD. The efficacy is higher than reported in anti-TNF experienced patients and is comparable to that of anti-TNF biologics in this population.